Factors associated with improvement in symptoms and quality of life for first-line EGFR-tyrosine kinase inhibitor treatment in patients with EGFR-mutated non-small-cell lung cancer

Wei Y.-F.Huang W.-T.Liu T.-C.Shieh J.-M.Chian C.-F.Wu M.-F.Chang C.-C.Lin C.-H.JEN-CHUNG KOLin C.-M.Hsia T.-C.2021-03-112021-03-1120191837-9664https://www.scopus.com/inward/record.uri?eid=2-s2.0-85070484558&doi=10.7150%2fjca.30507&partnerID=40&md5=47d24e379f3cc064968391c9ac7047edhttps://scholars.lib.ntu.edu.tw/handle/123456789/551914[SDGs]SDG3Factors associated with improvement in symptoms and quality of life for first-line EGFR-tyrosine kinase inhibitor treatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter prospective SMILE studyjournal article10.7150/jca.305072-s2.0-85070484558